Huaisy Pharmaceutical: 4 products are expected to be selected in the 12th batch of national centralized procurement of medicines.

Huahai Pharmaceutical announced that on July 31, 2026, the company will participate in the bidding for the twelfth batch of national centralized drug procurement, with Lamotrigine tablets, Elamopride tablets, Perindopril Amlodipine tablets, and Mesalazine enteric-coated tablets expected to be selected. The procurement period will run from the implementation date of the selection results until December 31, 2029. In 2025, the domestic sales of Lamotrigine tablets were approximately 40.3771 million yuan, accounting for 0.47% of that year's revenue; in the first quarter of 2026, sales were about 9.753 million yuan, accounting for 0.42%. The other three products had no sales by the end of the first quarter of 2026. If selected, this would have a positive impact on the company's operations, but the impact on performance remains uncertain.